Related Experiment Video
Updated: May 14, 2026
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Mechanistic evaluation of a novel small molecule targeting mitochondria in pancreatic cancer cells
Yumna H Shabaik1, Melissa Millard, Nouri Neamati
1Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California, USA.
Background:
Pancreatic cancer is one of the deadliest cancers with a 5-year survival rate of 6%. Therapeutic options are very limited and there is an unmet medical need for safe and efficacious treatments. Cancer cell metabolism and mitochondria provide unexplored targets for this disease. We recently identified a novel class of triphenylphosphonium salts, TP compounds, with broad- spectrum anticancer properties. We examined the ability of our prototypical compound TP421- chosen for its fluorescent properties - to inhibit the growth of pancreatic cancer cells and further investigated the molecular mechanisms by which it exerts its anticancer effects.
Methodology/Principal Findings:
TP421 exhibited sub-micromolar IC(50) values in all the pancreatic cancer cell lines tested using MTT and colony formation assays. TP421 localized predominantly to mitochondria and induced G(0)/G(1) arrest, ROS accumulation, and activation of several stress-regulated kinases. Caspase and PARP-1 cleavage were observed indicating an apoptotic response while LC3B-II and p62 were accumulated indicating inhibition of autophagy. Furthermore, TP421 induced de-phosphorylation of key signaling molecules involved in FAK mediated adhesion that correlated with inhibition of cell migration.
Conclusions/Significance:
TP421 is a representative compound of a new promising class of mitochondrial-targeted agents useful for pancreatic cancer treatment. Because of their unique mechanism of action and efficacy further development is warranted.
Insights
A novel triphenylphosphonium salt, TP421, effectively inhibits pancreatic cancer cell growth by targeting mitochondria. This compound induces apoptosis and inhibits autophagy, showing promise for pancreatic cancer treatment.
Area of Science:
- Mitochondrial biology
- Cancer therapeutics
- Molecular oncology
Background:
- Pancreatic cancer has a low survival rate and limited treatment options.
- Targeting cancer cell metabolism and mitochondria presents a novel therapeutic strategy.
- Triphenylphosphonium salts (TP compounds) are a newly identified class with broad-spectrum anticancer activity.
Purpose of the Study:
- To evaluate the efficacy of TP421, a prototypical TP compound, against pancreatic cancer cells.
- To elucidate the molecular mechanisms underlying TP421's anticancer effects.
Main Methods:
- MTT and colony formation assays were used to assess TP421's cytotoxicity.
- Mitochondrial localization, cell cycle arrest, reactive oxygen species (ROS) accumulation, and kinase activation were analyzed.
- Apoptosis, autophagy inhibition, and focal adhesion kinase (FAK) signaling pathways were investigated.
Main Results:
- TP421 demonstrated potent anti-proliferative activity with sub-micromolar IC50 values in pancreatic cancer cell lines.
- TP421 localized to mitochondria, induced G0/G1 cell cycle arrest, increased ROS, and activated stress kinases.
- TP421 triggered apoptosis, inhibited autophagy, and reduced cell migration by de-phosphorylating FAK-mediated adhesion molecules.
Conclusions:
- TP421 represents a promising new class of mitochondrial-targeted agents for pancreatic cancer therapy.
- The compound's unique mechanism of action and demonstrated efficacy warrant further development.
